Targeting pancreatic cancer metabolic dependencies through glutamine antagonism.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors resulted in rapid metabolic reprogramming and therapeutic resistance. Here, we demonstrated that treating PDAC cells with a Gln antagonist, 6-diazo-5-oxo-L-norleucine (DON), led to a metabolic crisis in vitro. In addition, we observed a profound decrease in tumor growth in several in vivo models using sirpiglenastat (DRP-104), a pro-drug version of DON that was designed to circumvent DON-associated toxicity. We found that extracellular signal-regulated kinase (ERK) signaling is increased as a compensatory mechanism. Combinatorial treatment with DRP-104 and trametinib led to a significant increase in survival in a syngeneic model of PDAC. These proof-of-concept studies suggested that broadly targeting Gln metabolism could provide a therapeutic avenue for PDAC. The combination with an ERK signaling pathway inhibitor could further improve the therapeutic outcome.

• Authors: Joel Encarnación-Rosado, Albert S W Sohn, Douglas E Biancur, Elaine Y Lin, Victoria Osorio-Vasquez, Tori Rodrick, Diana González-Baerga, Ende Zhao, Yumi Yokoyama, Diane M Simeone, Drew R Jones, Seth J Parker, Robert Wild, Alec C Kimmelman
• Journal: Nature cancer (Nat Cancer) Vol. 5 Issue 1 Pg. 85-99 (Jan 2024) ISSN: 2662-1347 [Electronic] England
• PMID: 37814010 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• Glutamine
• Antineoplastic Agents
• Enzyme Inhibitors

Topics

• Humans
• Glutamine (metabolism)
• Cell Line, Tumor
• Pancreatic Neoplasms (drug therapy, metabolism)
• Antineoplastic Agents (pharmacology)
• Carcinoma, Pancreatic Ductal (drug therapy, metabolism)
• Enzyme Inhibitors (pharmacology)